{"id":"cicaprost","rwe":[{"pmid":"40587812","year":"2025","title":"PGI2 signaling metabolically reprograms CD4 Th2 cells and represses allergic airway inflammation.","finding":"","journal":"Journal of immunology (Baltimore, Md. : 1950)","studyType":"Clinical Study"},{"pmid":"38044577","year":"2024","title":"Inhibition of TRPM8 function by prostacyclin receptor agonists requires coupling to Gq/11 proteins.","finding":"","journal":"British journal of pharmacology","studyType":"Clinical Study"},{"pmid":"34260805","year":"2021","title":"Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress.","finding":"","journal":"Stem cells (Dayton, Ohio)","studyType":"Clinical Study"},{"pmid":"32690653","year":"2020","title":"COX Inhibition Increases Alternaria-Induced Pulmonary Group 2 Innate Lymphoid Cell Responses and IL-33 Release in Mice.","finding":"","journal":"Journal of immunology (Baltimore, Md. : 1950)","studyType":"Clinical Study"},{"pmid":"31207273","year":"2019","title":"Mannitol triggers mast cell-dependent contractions of human small bronchi and prostacyclin bronchoprotection.","finding":"","journal":"The Journal of allergy and clinical immunology","studyType":"Clinical Study"}],"tags":[{"label":"cicaprost","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostacyclin receptor","category":"target"},{"label":"PTGIR","category":"gene"},{"label":"PTGER4","category":"gene"},{"label":"PTGER3","category":"gene"},{"label":"Active","category":"status"},{"label":"Antineoplastic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["cicaprost dihydrochloride","ZK-96480","cicaprost betadex","cicaprost"],"offLabel":[],"synonyms":["cicaprost dihydrochloride","ZK-96480","cicaprost betadex","cicaprost"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype","targets":[{"gene":"PTGIR","source":"DrugCentral","target":"Prostacyclin receptor","protein":"Prostacyclin receptor"},{"gene":"PTGER4","source":"DrugCentral","target":"Prostaglandin E2 receptor EP4 subtype","protein":"Prostaglandin E2 receptor EP4 subtype"},{"gene":"PTGER3","source":"DrugCentral","target":"Prostaglandin E2 receptor EP3 subtype","protein":"Prostaglandin E2 receptor EP3 subtype"},{"gene":"PTGER1","source":"DrugCentral","target":"Prostaglandin E2 receptor EP1 subtype","protein":"Prostaglandin E2 receptor EP1 subtype"},{"gene":"PTGDR","source":"DrugCentral","target":"Prostaglandin D2 receptor","protein":"Prostaglandin D2 receptor"},{"gene":"PTGFR","source":"DrugCentral","target":"Prostaglandin F2-alpha receptor","protein":"Prostaglandin F2-alpha receptor"}],"modality":"Small Molecule","drugClass":"cicaprost","explanation":"Imagine your blood vessels are like roads in your body. Prostacyclin is like a traffic light that helps keep the roads open and flowing. Cicaprost is like a duplicate traffic light that helps keep the roads open and flowing, even when the original light is not working.","oneSentence":"Cicaprost works by binding to and activating the prostacyclin receptor, mimicking the effects of prostacyclin to promote vasodilation and inhibit platelet aggregation.","technicalDetail":"Cicaprost acts as a prostacyclin receptor agonist, binding to the G protein-coupled receptor (GPCR) and activating the adenylate cyclase pathway, leading to increased levels of cyclic AMP (cAMP) and subsequent vasodilation and inhibition of platelet aggregation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/631","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CICAPROST","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:36:48.709199","biosimilars":[],"competitors":[{"drugName":"alprostadil","drugSlug":"alprostadil","fdaApproval":"1981-10-16","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"bupivacaine","drugSlug":"bupivacaine","fdaApproval":"1972-10-03","patentExpiry":"Mar 17, 2042","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"cloprostenol","drugSlug":"cloprostenol","fdaApproval":"","relationship":"same-target"},{"drugName":"dinoprost","drugSlug":"dinoprost","fdaApproval":"1976-05-18","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"dinoprostone","drugSlug":"dinoprostone","fdaApproval":"1977-08-23","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"epoprostenol","drugSlug":"epoprostenol","fdaApproval":"1995-09-20","patentExpiry":"Mar 15, 2027","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"iloprost","drugSlug":"iloprost","fdaApproval":"2004-12-29","patentExpiry":"Jul 18, 2044","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"latanoprost","drugSlug":"latanoprost","fdaApproval":"1996-06-05","patentExpiry":"Sep 12, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"levobupivacaine","drugSlug":"levobupivacaine","fdaApproval":"1999-08-05","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"mezlocillin","drugSlug":"mezlocillin","fdaApproval":"1981-09-21","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"cicaprost","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alprostadil","brandName":"alprostadil","genericName":"alprostadil","approvalYear":"1981","relationship":"same-target"},{"drugId":"bupivacaine","brandName":"bupivacaine","genericName":"bupivacaine","approvalYear":"1972","relationship":"same-target"},{"drugId":"cloprostenol","brandName":"cloprostenol","genericName":"cloprostenol","approvalYear":"","relationship":"same-target"},{"drugId":"dinoprost","brandName":"dinoprost","genericName":"dinoprost","approvalYear":"1976","relationship":"same-target"},{"drugId":"dinoprostone","brandName":"dinoprostone","genericName":"dinoprostone","approvalYear":"1977","relationship":"same-target"},{"drugId":"epoprostenol","brandName":"epoprostenol","genericName":"epoprostenol","approvalYear":"1995","relationship":"same-target"},{"drugId":"iloprost","brandName":"iloprost","genericName":"iloprost","approvalYear":"2004","relationship":"same-target"},{"drugId":"latanoprost","brandName":"latanoprost","genericName":"latanoprost","approvalYear":"1996","relationship":"same-target"},{"drugId":"levobupivacaine","brandName":"levobupivacaine","genericName":"levobupivacaine","approvalYear":"1999","relationship":"same-target"},{"drugId":"mezlocillin","brandName":"mezlocillin","genericName":"mezlocillin","approvalYear":"1981","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"NE94J8CAMD","CHEBI":"CHEBI:135578","INN_ID":"5826","UMLSCUI":"C0055705","ChEMBL_ID":"CHEMBL160629","PUBCHEM_CID":"5311044","IUPHAR_LIGAND_ID":"1917","MESH_SUPPLEMENTAL_RECORD_UI":"C043867"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.1 hours","clearance":"3.8 mL/min/kg","bioavailability":"99%","volumeOfDistribution":"0.08 L/kg"},"publicationCount":225,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Sep 1","pmid":"40587812","title":"PGI2 signaling metabolically reprograms CD4 Th2 cells and represses allergic airway inflammation.","journal":"Journal of immunology (Baltimore, Md. : 1950)"},{"date":"2024 May","pmid":"38044577","title":"Inhibition of TRPM8 function by prostacyclin receptor agonists requires coupling to Gq/11 proteins.","journal":"British journal of pharmacology"},{"date":"2021 Nov","pmid":"34260805","title":"Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress.","journal":"Stem cells (Dayton, Ohio)"},{"date":"2020 Aug 15","pmid":"32690653","title":"COX Inhibition Increases Alternaria-Induced Pulmonary Group 2 Innate Lymphoid Cell Responses and IL-33 Release in Mice.","journal":"Journal of immunology (Baltimore, Md. : 1950)"},{"date":"2019 Oct","pmid":"31207273","title":"Mannitol triggers mast cell-dependent contractions of human small bronchi and prostacyclin bronchoprotection.","journal":"The Journal of allergy and clinical immunology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"CICAPROST","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cicaprost is a small molecule drug that targets the prostacyclin receptor. It is classified as a cicaprost, a type of medication that works by mimicking the effects of prostacyclin, a naturally occurring substance in the body. However, its commercial status and approved indications are unknown. As a prostacyclin receptor agonist, cicaprost is likely used to treat conditions related to blood vessel constriction and inflammation. Further research is needed to determine its full potential and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}